EGFR and cancer: A study conducted by Corte et al. highlighted that avelumab, in combination with the anti-epidermal growth factor receptor (EGFR) drug cetuximab, led to cancer cell growth reduction in three-dimensional in vitro spheroid cultures made from NSCLC patient cells compared to single-agent treatment.